BTG Share News (BTG)

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar - Week Ahead

FTSE 250 movers: Retail stocks lead rise as footfall decline slows

Retail stocks were putting in a strong performance on Tuesday after data from BRC-Springboard showed the decline in UK retail footfall eased to 0.9% in September from a 1.1% drop in August. Stocks such as Debenhams, Home Retail, Just Eat, WH Smith and Halfords were all in positive territory. "With a

Tuesday broker round-up UPDATE

Anglo Pacific: FinnCap upgrades to buy with a target price of 158p. Peel Hunt shifts target price from 196p to 198p retaining its buy recommendation. Ashmore: Canaccord Genuity upgrades from sell to hold with a target price of 300p. Numis cuts target price from 369p to 355p retaining an add rating.

UK BROKER RATINGS: HSBC Upgrades IAG To Overweight From Neutral

UK MIDDAY BRIEFING: Synergy Health Soars On Steris Takeover Deal

TOP NEWS: Synergy Health Agrees To USD1.9 Billion US Takeover

Monday broker round-up UPDATE

Amino Technologies: Northland Capital upgrades to buy with a target price of 100p. Anglo American: Canaccord Genuity initiates with a target price of 1720p and a buy recommendation. Credit Suisse upgrades to outperform with a target price of 1800p. Associated British Foods: Societe Generale upgrade

BTG to sell two drug treatments directly to 11 European countries

Healthcare group BTG has announced its plans to start selling two of its oncology treatments directly to 11 European countries from 1 April next year. The move comes after the FTSE 250 group earlier this year began building a direct sales force to promote the approved uses of its products in major E

UK MORNING BRIEFING: London Shares Slide At Open On Eurozone Worries

BTG To Start Direct Sales Of DC Bead, Bead Block In 11 European Countries

FTSE 250 movers: Telecom Plus climbs as oil stocks slide

Utility services group Telecom Plus said it is happy with market expectations for the full year after strong organic growth in the first half, causing shares to surge on Friday. The company said that the strong growth in both customers and service numbers seen at the start of the year accelerated in

BTG to pay $6m to settle legal dispute with Bioclon over snake venom drug

Specialist healthcare company BTG has settled its US patent infringement complaint against Instituto Bioclon and Rare Disease Therapeutics with a $6m payment. The FTSE 250-listed group has agreed to allow Bioclon to start selling its crotalid treatment from October 2018 if the Mexico-based firm rece

BTG Settles Patent Complaint With Bioclon, Rare Disease Therapeutics

Thursday broker round-up UPDATE

African Barrick Gold: Numis reduces target price from 330p to 270p keeping its hold recommendation. Antofagasta: Numis upgrades to hold with a target price of 700p. Aureus Mining: Numis lowers target price from 45p to 40p staying with its buy recommendation. Boohoo: Barclays initiates with a targe